CHICAGO — Lorlatinib delivered never-before-seen PFS results in adults with anaplastic lymphoma kinase-positive non-small cell lung cancer, according to findings from a randomized phase 3 trial presented at ASCO Annual Meeting.Lorlatinib (Lorbrena, Pfizer) also drastically delayed disease progression and development of brain metastases compared with crizotinib (Xalkori, Pfizer).
Pfizer drug extends life for people with rare form of lung cancer
thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.
Illumina Presents Research to Boost Case for Genomic Testing in Oncology Care
timesofsandiego.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from timesofsandiego.com Daily Mail and Mail on Sunday newspapers.